The Effect of Selenium Intake on the Risk of Liver Cancer of HBsAg Carriers: a Cohort Study

CHEN Tao-yang,YAO Hong-yu,NI Zheng-ping,ZHU Jian,ZHANG Qi-nan,ZHANG Yong-hui,SHEN Hong-bing,CHEN Jian-guo
DOI: https://doi.org/10.3781/j.issn.1000-7431.2006.12.007
2006-01-01
Tumor
Abstract:Objective:To evaluate the effect of the selenium intake on the risk of liver cancer in HBsAg carriers.Methods:The experimental epidemiological design was used.In the intervention trial HBsAg carriers were recruited and radomly given selenium to prevent liver cancer in Qidong area,an area with high incidence of liver cancer,from 1996 to 1999,and were followed up till 2004.The data based on death were collected.Results:Five years(from 2000 to 2004) after termination of the intervention with selenium,cumulative mortality rate due to liver cancer(4.384%)and chronic hepatitis or hepatocirrhosis(0.939%)were significantly lower in the intervention group than the placebo group(mortality rate due to liver cancer: 7.533%,U=2.827,P=0.005;mortality rate due to chronic hepatitis or hepatocirrhosis : 2.552%,U=2.636,P=0.009.The relative risk of liver cancer-induced death in the intervention group was 0.582 fold of the control group(RR=0.582,95% CI : 0.389-0.871)and the relative risk of chronic hepatitis or hepatocirrhosis-induced death was 0.368 fold of the control group(RR=0.368,95% CI:(0.168)-0.808).There was a relatively strong relationship between selenium intake and chronic hepatitis or hepatocirrhosis-induced death.The protective rates of selenium intake against liver cancer and chronic hepatitis or hepatocirrhosis were 41.804% and(63.182)%,respectively.Conclusion:The selenium intake may effectively decrease the incidence of liver cancer and other liver diseases among HBsAg carriers,and the efficacy lasted more than five years after the termination of intervention.
What problem does this paper attempt to address?